William H Shingler

Summary

Affiliation: Medawar Centre
Country: UK

Publications

  1. ncbi Identification and functional validation of MHC class I epitopes in the tumor-associated antigen 5T4
    William H Shingler
    Oxford BioMedica UK Ltd, Medawar Centre, Oxford Science Park, Oxford, OX4 4GA, UK
    Int Immunol 20:1057-66. 2008
  2. ncbi Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma
    Howard L Kaufman
    Tumor Immunology Laboratory, Division of Surgical Oncology, Columbia University, New York, NY, USA
    J Transl Med 7:2. 2009
  3. ncbi MVA-5T4-induced immune responses are an early marker of efficacy in renal cancer patients
    Richard Harrop
    Oxford BioMedica UK Ltd, The Medawar Centre, Oxford Science Park, Oxford, OX4 4GA, UK
    Cancer Immunol Immunother 60:829-37. 2011

Collaborators

  • Robert J Amato
  • Howard L Kaufman
  • Richard Harrop
  • Peter Treasure
  • Mike McDonald
  • Michelle Kelleher
  • Madusha Goonewardena
  • Jackie De Belin
  • Robert E Hawkins
  • Stuart Naylor

Detail Information

Publications3

  1. ncbi Identification and functional validation of MHC class I epitopes in the tumor-associated antigen 5T4
    William H Shingler
    Oxford BioMedica UK Ltd, Medawar Centre, Oxford Science Park, Oxford, OX4 4GA, UK
    Int Immunol 20:1057-66. 2008
    ..Conclusion: iTopia represents a rapid and high-throughput technique to identify CTL epitopes...
  2. ncbi Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma
    Howard L Kaufman
    Tumor Immunology Laboratory, Division of Surgical Oncology, Columbia University, New York, NY, USA
    J Transl Med 7:2. 2009
    ..A modified vaccinia virus Ankara (MVA) encoding 5T4 was tested in combination with high-dose IL-2 to determine the safety, objective response rate and effect on humoral and cell-mediated immunity...
  3. ncbi MVA-5T4-induced immune responses are an early marker of efficacy in renal cancer patients
    Richard Harrop
    Oxford BioMedica UK Ltd, The Medawar Centre, Oxford Science Park, Oxford, OX4 4GA, UK
    Cancer Immunol Immunother 60:829-37. 2011
    ....